Compositions and methods for identifying and treating microparticle-associated diseases and conditions
AssigneesBioAegis Therapeutics Inc., University of Maryland, Baltimore
InventorsSusan L. Levinson, Stephen R. Thom, Mark J. DiNubile, Thomas P. Stossel
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for identifying and treating signature MP-associated diseases and conditions in subjects. In particular, treatment methods of the invention include administering a gelsolin agent to produce a therapeutic effect against a signature MP-associated disease or condition in a subject.
Claims30
A method of determining the presence of a signature MP-associated disease or condition in a subject, comprising:
- (a) detecting in a biological sample obtained from a subject suspected of having a signature MP-associated disease or condition, the presence of microparticles;
- (b) identifying the detected microparticles as comprising an IL-1β signature, a lymphocyte antigen 6 complex locus G6D (Ly6G) signature, or a CD66b signature;
- wherein the identification of the IL-1β, Ly6G, or CD66b signature confirms the presence of the signature MP-associated disease or condition in the subject;
- (c) selecting a therapeutic regimen for the subject based at least in part on the confirmation of the presence of the signature MP-associated disease or condition in the subject;
- and
- (d) administering the selected therapeutic regimen to the subject to treat the signature MP-associated disease or condition.
6-7. (canceled)
(canceled)
12-13. (canceled)
(canceled)
18-20. (canceled)
23-29. (canceled)
34-36. (canceled)
A method for treating a signature MP-associated disease or condition in a subject, the method comprising, administering to a subject having or suspected of having the signature MP-associated disease or condition an effective amount of a gelsolin agent wherein the administered gelsolin agent has a greater therapeutic effect against the signature MP-associated disease or condition compared to a control therapeutic effect on the signature MP-associated disease or condition.
38-46. (canceled)
48-69. (canceled)
A method for reducing a subject's risk of developing a signature MP-associated disease or condition, comprising:
- administering to a subject identified as at risk of developing the signature MP-associated disease or condition an effective amount of a gelsolin agent to reduce the subject's risk of developing the signature MP-associated disease or condition.
71-104. (canceled)
Dependencies are inferred from the claim text.